Proprietary CAR-T Engineering Platform: Autolus utilizes its proprietary T-cell programming and manufacturing platforms, including its "Obi-Rap" switch and "AUTO" platforms, to develop differentiated CAR-T cell therapies designed for improved safety and efficacy.

Differentiated Product Candidates: Its lead programs, such as AUTO1/22 for B-ALL, are engineered to offer a potentially superior safety profile with robust anti-tumor activity compared to existing CAR-T therapies, addressing a critical unmet need for reduced neurotoxicity and cytokine release syndrome.

Broad Clinical Pipeline: Autolus maintains a diversified pipeline of autologous CAR-T cell product candidates targeting multiple hematological malignancies and solid tumors, reducing single-product dependency and expanding its potential market reach.